Value of serum chitinase-3-like protein 1 in predicting the risk of decompensation events in patients with liver cirrhosis

Hang YANG; Lili ZHAO; Ping HAN; Qingling CHEN; Jun WEN; Jie LIU; Xiaojing CHENG; Jia LI

doi:10.3969/j.issn.1001-5256.2023.07.011

Volume 39 Issue 7

Jul. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(7): 1578-1585

PDF( 2209 KB)

Value of serum chitinase-3-like protein 1 in predicting the risk of decompensation events in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2023.07.011

1.
Clinical School of The Second People's Hospital, Tianjin Medical University, Tianjin 300070, China
2.
Department of Hepatology, Tianjin Second People's Hospital, Tianjin 300192, China

Research funding:

Tianjin Key Medical Subject Construction Project (TJYXZDXK-059B);

Tianjin Natural Science Fund (20JCYBJC01150);

Tianjin Health Science Project (TJWJ2021MS034)

More Information

Corresponding author: LI Jia, 18622663700@163.com (ORCID: 0000-0003-0100-417X)
Received Date: 2022-11-11
Accepted Date: 2023-01-02
Published Date: 2023-07-20

Abstract

Abstract

Objective To investigate the value of serum chitinase-3-like protein 1 (CHI3L1) in predicting the risk of decompensation events in patients with liver cirrhosis, since prediction of decompensation events and adoption of active preventive measures are the key to improving the survival time of patients with liver cirrhosis. Methods A case-control study was conducted for 305 patients with liver cirrhosis who were diagnosed and treated in Tianjin Second People's Hospital from January 2019 to May 2021, among whom there were 200 patients with compensated liver cirrhosis and 105 patients with decompensated liver cirrhosis at baseline. According to whether decompensation events occurred within 1 year, the 305 patients with liver cirrhosis were divided into decompensation group with 79 patients and non-decompensation group with 226 patients; according to whether decompensation events occurred for the first time within 1 year, the 200 patients with compensated liver cirrhosis were divided into first-time decompensation group with 43 patients and non-first-time decompensation group with 157 patients. The independent samples t-test or the Mann-Whitney U test was used for comparison of normally distributed continuous data between groups, and the Wilcoxon rank-sum test or the chi-square test was used for comparison of categorical data between groups. The binary logistic regression analysis was used to investigate the association between each variable and decompensation events; the receiver operating characteristic (ROC) curve and the area under the ROC curve (AUC) were used to investigate the value of each variable in predicting decompensation events, and the maximum value of Youden index was used to determine the optimal cut-off value. Results The patients who experienced decompensation events within 1 year had a significantly higher baseline serum level of CHI3L1 than those who did not experience such events [243.00 (136.00-372.00) ng/mL vs 117.50 (67.75-205.25) ng/mL, U=4720.500, P < 0.001], and the patients who experienced decompensation events for the first time within 1 year had a significantly higher baseline serum level of CHI3L1 than those who did not experience such events [227.98 (110.00-314.00) ng/mL vs 90.00 (58.00-168.50) ng/mL, U=1 681.500, P < 0.001]. Patients with cirrhosis with higher baseline CHI3L1 levels had an increased risk of decompensation events within 1 year (OR=1.004, 95%CI: 1.002-1.006, P < 0.001); Patients with compensated cirrhosis with higher baseline serum CHI3L1 levels had an increased risk of first decompensated event within 1 year (OR=1.006, 95%CI: 1.003-1.008, P < 0.001). The baseline serum level of CHI3L1 had an AUC of 0.751 in predicting the risk of first-time decompensation events, with a sensitivity of 90.7% and a specificity of 55.4% at the optimal cut-off value of 95.5 ng/mL. The predictive model based on the combination of serum CHI3L1 level and Child-Pugh class had an AUC of 0.809, with a sensitivity of 72.1% and a specificity of 77.1% at the maximum value of Youden index. Conclusion Serum CHI3L1 level can be used as an effective predictive factor for the risk of first-time decompensation events in patients with compensated liver cirrhosis, and its combination with Child-Pugh class shows a higher predictive value.
- Liver Cirrhosis,
- Chitinase-3-Like Protein 1,
- Risk Factors

FullText(HTML)

References(20)

References

[1]	de FRANCHIS R, BOSCH J, GARCIA-TSAO G, et al. Baveno VⅡ - Renewing consensus in portal hypertension[J]. J Hepatol, 2022, 76(4): 959-974. DOI: 10.1016/j.jhep.2021.12.022.
[2]	GINÈS P, KRAG A, ABRALDES JG, et al. Liver cirrhosis[J]. Lancet, 2021, 398(10308): 1359-1376. DOI: 10.1016/S0140-6736(21)01374-X.
[3]	KOUANDA A, BINMOELLER K, HAMERSKI C, et al. Safety and efficacy of EUS-guided coil and glue injection for the primary prophylaxis of gastric variceal hemorrhage[J]. Gastrointest Endosc, 2021, 94(2): 291-296. DOI: 10.1016/j.gie.2021.01.025.
[4]	Chinese Society of Hepatology, Chinese Medical Association. Chinese guidelinesonthe management of liver cirrhosis[J]. J Clin Hepatol, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006. 中华医学会肝病学分会. 肝硬化诊治指南[J]. 临床肝胆病杂志, 2019, 35(11): 2408-2425. DOI: 10.3969/j.issn.1001-5256.2019.11.006.
[5]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B(version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[6]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[7]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association: Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[8]	Fatty Liver Expert Committee, Chinese Medical Doctor Association; National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of prevention and treatment for alcoholic liver disease: a 2018 update[J]. J Clin Hepatol, 2018, 34(5): 939-946. DOI: 10.3969/j.issn.1001-5256.2018.05.006. 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝和酒精性肝病学组. 酒精性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 939-946. DOI: 10.3969/j.issn.1001-5256.2018.05.006.
[9]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of autoimmune hepatitis (2021)[J]. J Clin Hepatol, 2022, 38(1): 42-49. DOI: 10.3969/j.issn.1001-5256.2022.01.008. 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 42-49. DOI: 10.3969/j.issn.1001-5256.2022.01.008.
[10]	Chinese Society of Hepatology, Chinese Medical Association. Guidelines on the diagnosis and management of primary biliary cholangitis(2021)[J]. J Clin Hepatol, 2022, 38(1): 35 -41. DOI: 10.3969/j.issn.1001-5256.2022.01.007. 中华医学会肝病学分会. 原发性胆汁性胆管炎的诊断和治疗指南(2021)[J]. 临床肝胆病杂志, 2022, 38(1): 35-41. DOI: 10.3969/j.issn.1001-5256.2022.01.007.
[11]	OBER C, TAN Z, SUN Y, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function[J]. N Engl J Med, 2008, 358(16): 1682-1691. DOI: 10.1056/NEJMoa0708801.
[12]	HUANG X, ZHUANG J, YANG Y, et al. Diagnostic value of serum chitinase-3-like protein 1 for liver fibrosis: A Meta-analysis[J]. Biomed Res Int, 2022, 2022: 3227957. DOI: 10.1155/2022/3227957.
[13]	GARCIA-TSAO G, ABRALDES JG. Nonselective beta-blockers in compensated cirrhosis: Preventing variceal hemorrhage or preventing decompensation?[J]. Gastroenterology, 2021, 161(3): 770-773. DOI: 10.1053/j.gastro.2021.04.077.
[14]	LIU Y, LIU C, LI J, et al. Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102)[J]. J Hepatol, 2022, 76(1): 248-250. DOI: 10.1016/j.jhep.2021.10.006.
[15]	Chinese Society of Hepatology. Chinese Medical Association; Chinese Socie ty of Gastroenterology, Chinese Medical Association; Chinese Society of Endoscopy. Chinese Medical Association Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertensio[J]. J Clin Hepatol, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002. 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]. 临床肝胆病杂志, 2016, 32(2): 203-219. DOI: 10.3969/j.issn.1001-5256.2016.02.002.
[16]	LIU H, SUN J, LIU G, et al. Establishment of a non-invasive prediction model for the risk of oesophageal variceal bleeding using radiomics based on CT[J]. Clin Radiol, 2022, 77(5): 368-376. DOI: 10.1016/j.crad.2022.01.046.
[17]	ZHAO L, WANG T, GUO C, et al. Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis[J]. Hepatol Int, 2022, 16(4): 936-943. DOI: 10.1007/s12072-022-10359-y.
[18]	LUO YX, ZHOU T. Value of systemic immune inflammatory index on predicting the proanosis of patients with decompensated liver cirrhosis[J/CD]. Chin J Liver Dis(Electronic Version) 2021, 13(1): 52-58. DOI: 10.3969/j.issn.1674-7380.2021.01.009. 罗永祥, 周涛. 全身免疫炎症指数对失代偿期肝硬化患者预后的评估价值[J/CD]. 中国肝脏病杂志(电子版), 2021, 13(1): 52-58. DOI: 10.3969/j.issn.1674-7380.2021.01.009.
[19]	COSTA D, SIMBRUNNER B, JACHS M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality[J]. J Hepatol, 2021, 74(4): 819-828. DOI: 10.1016/j.jhep.2020.10.004.
[20]	COULON S, HEINDRYCKX F, GEERTS A, et al. Angiogenesis in chronic liver disease and its complications[J]. Liver Int, 2011, 31(2): 146-162. DOI: 10.1111/j.1478-3231.2010.02369.x.

Relative Articles

[1]	Jing KUANG, Shuangqin TENG, Tongtong SHEN, Yiran YAN, Wei WANG, Chuan SHEN, Caiyan ZHAO. Risk factors for portopulmonary hypertension in liver cirrhosis and construction of a predictive model[J]. Journal of Clinical Hepatology, 2024, 40(9): 1802-1806. doi: 10.12449/JCH240914
[2]	Tianfu LIU, Liang WANG, Lingyi ZHANG. Risk factors for non－neoplastic portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2023, 39(9): 2122-2127. doi: 10.3969/j.issn.1001-5256.2023.09.014
[3]	Siqin LIU, Xiaomei WANG, Xia LI, Luwen LIANG, Ke WANG, Rui WANG. Covert hepatic encephalopathy in liver cirrhosis: Risk factors and prognosis[J]. Journal of Clinical Hepatology, 2022, 38(2): 359-364. doi: 10.3969/j.issn.1001-5256.2022.02.020
[4]	Bingbing ZHU, Jinxiang YANG, Qun ZHANG, Fangyuan GAO, Xianbo WANG. Risk factors for the 90-day prognosis of patients with type I hepatorenal syndrome and establishment of a predictive model[J]. Journal of Clinical Hepatology, 2022, 38(7): 1561-1565. doi: 10.3969/j.issn.1001-5256.2022.07.019
[5]	Shanshan LI, Manman XU, Zhongping DUAN, Yu CHEN. Risk factors for liver cirrhosis in acute-on-chronic liver failure patients without liver cirrhosis in the convalescence stage[J]. Journal of Clinical Hepatology, 2021, 37(12): 2824-2829. doi: 10.3969/j.issn.1001-5256.2021.12.019
[6]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[7]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[8]	LI ZhengHong, DONG YuWei, LU LunGen. Risk factors,diagnosis,and updated classification of hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2020, 36(11): 2411-2414. doi: 10.3969/j.issn.1001-5256.2020.11.003
[9]	Ruan FangMing, Li BiMin. Risk factors for the formation of portal vein thrombosis in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(1): 182-185. doi: 10.3969/j.issn.1001-5256.2020.01.043
[10]	Sun YaNan, Li Peng, Ding HuiGuo, Zhang ShiBin, Xiong Feng. Risk factors for early rebleeding after initial sclerotherapy for esophageal varices[J]. Journal of Clinical Hepatology, 2019, 35(1): 92-97. doi: 10.3969/j.issn.1001-5256.2019.01.017
[11]	Lyu Jing, Dong SiSi, Gu HongTu, Zhao ZhangQing, Liu ChengHai. TCM syndrome characteristics of portal vein thrombosis in patients with liver cirrhosis and related risk factors[J]. Journal of Clinical Hepatology, 2019, 35(10): 2210-2213. doi: 10.3969/j.issn.1001-5256.2019.10.016
[12]	He Yang, Su YaRong, Han ZiYan. Current status of research on primary and secondary risk factors for esophagogastric variceal rebleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2018, 34(7): 1555-1559. doi: 10.3969/j.issn.1001-5256.2018.07.041
[13]	Jin Yan, Wang Xue, Zhang LingJuan, Qiu Ting, Shang BoXin, Lian XiaoYan, Yan ChunYing, Duan TianJiao, Zhang Rong, Liu GuiSheng. Risk factors for early rebleeding after esophageal variceal ligation in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(11): 2147-2151. doi: 10.3969/j.issn.1001-5256.2017.11.019
[14]	Yu ZhiRui, Wei GuoXi, Liu QiChang, Jin PeiMin. Risk factors for HBV-related liver cirrhosis complicated by acute upper gastrointestinal bleeding[J]. Journal of Clinical Hepatology, 2017, 33(5): 860-863. doi: 10.3969/j.issn.1001-5256.2017.05.013
[15]	Zhou RenHua, Li Peng, Zhang YanTing, Yang Hua, Yang ShaoQi. Clinical manifestations of portal vein thrombosis and related risk factors in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2016, 32(2): 275-278. doi: 10.3969/j.issn.1001-5256.2016.02.015
[16]	Chen BiHua, Zhang Wei, Wu Pei, Huang Ying. Research advances in risk factors for primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(12): 2088-2092. doi: 10.3969/j.issn.1001-5256.2015.12.024
[17]	Yang Hua, Liu YunXia, Li Peng, Yang ShaoQi, Wang YuanZhen. Analysis of risk factors for early rebleeding from esophageal and gastric varices in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(6): 540-542. doi: 10.3969/j.issn.1001-5256.2014.06.015
[18]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[19]	Wang Hong, Wang YingMin, Zhang Bo. Prospective analysis of risk factors for the occurrence of hepatocellular carcinoma in patients with post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(1): 34-35.
[20]	Wang Hong. Risk factors for patients with cirrhosis developed renal dysfunction[J]. Journal of Clinical Hepatology, 2004, 20(2): 101-102.

Supplements(0)

Cited By

Cited by

Periodical cited type(5)

1.	刘平箕，姚黎超，胡雪，王铮，熊芷玉，江应安. 人脐带间充质干细胞（hUC-MSC）对肝纤维化小鼠模型的治疗作用及其机制分析. 临床肝胆病杂志. 2024(03): 527-532 . 本站查看
2.	谭梅傲，黄祎，刘姝婉，王雅楠，刘华宝. 基于“肝为气之治”理论探讨肝硬化全病程中医防治机理及实践. 中西医结合肝病杂志. 2024(04): 292-295+300 .
3.	杨宁，折慧，屈文静，何学学. 血清HBD-1、CHI3L1水平在乙型肝炎病毒感染相关慢加急性肝衰竭预后预测中的效能. 山东医药. 2024(28): 1-6 .
4.	李晓宇，黄秀香，叶迎宾. 血清壳多糖酶3样蛋白1和PLT的比值与FIB-4指数在慢性乙型肝炎轻、中度诊断效价的比较. 标记免疫分析与临床. 2024(09): 1693-1697 .
5.	黄滨宁. 乙型肝炎肝硬化患者血清LN、HA、CⅣ、PⅢ、CHI3L1水平对肝纤维化程度的评估价值. 中国医药指南. 2024(34): 37-39 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(1) / Tables(5)

Get Citation

PDF

XML

Article Metrics

Article views (819) PDF downloads(56)

Value of serum chitinase-3-like protein 1 in predicting the risk of decompensation events in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2023.07.011